Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. Source: BioSpace You Might Also Like Little reMYND Forges 350M+ Euros Tie-Up With Drug Giant Novo Nordisk December 13, 2017 Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug November 1, 2017 Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran November 16, 2017
Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran November 16, 2017
